Chlorproguanil/dapsone

Drug Profile

Chlorproguanil/dapsone

Alternative Names: Dapsone/chlorproguanil; LAPDAP

Latest Information Update: 19 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline; World Health Organization
  • Class Antimalarials; Biguanides; Sulfones
  • Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Market Withdrawal Falciparum malaria; Malaria

Most Recent Events

  • 08 Dec 2003 Data presented at the 52nd Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH-2003) have been added to the adverse events and Parasitic Infections therapeutic trials section
  • 30 Sep 2003 First global launch of LAPDAP™
  • 30 Sep 2003 Launched for Falciparum malaria in Africa (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top